How has your journey in science been shaped by the people around you? Love Letters to Science explores five scientists' passionate relationship to their research, and how it helped them find their collaborations, people and community. Watch all five parts - now available on demand: https://bit.ly/3UHkY8l #ProgressHappensTogether #Abcam #LoveLettersToScience
About us
At Abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health.
- Website
-
https://www.abcam.com/
External link for abcam
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Cambridgeshire
- Type
- Public Company
- Specialties
- antibodies, custom services, proteins, gene-edited cell lines, knockout cell lines, rabbit antibodies, immunoassays, biological reagents, monoclonal antibodies, research, drug discovery , diagnostics, RabMAb, and Life Sciences
Locations
Employees at abcam
Updates
-
Are you frustrated by inconsistent results? We are too. That’s why we’ve partnered with Nature to explain how we’re using a new industry quality standard, Biophysical QC, to guarantee the best-performing antibody every time. Read our article here: https://lnkd.in/e_B8DdyA
-
📝 #CallforAbstracts: showcase your innovative research to a community of like-minded #cellcycle researchers. Short talk and poster opportunities are available to in-person attendees. Submit an abstract by May 17! https://bit.ly/3WeTidj
-
Your support network is there to help you through thick and thin. And so are we. From friendly scientific advice to recombinant antibodies that work every time, we’re here for you. https://bit.ly/3bFUoaO
-
Don’t miss Graham Heieis' film - part five of @abcam's Love Letters to Science! OUT NOW! https://bit.ly/3QOcQBV #ProgressHappensTogether #LoveLettersToScience #Abcam #PeopleBehindTheScience
-
What does an effective mentor-mentee relationship look like to you? Join us at PEGS Boston this year to find out from our VP of Protein Development, Deborah Moore-La. Deborah will share insights into what this looks like for her in an exclusive panel discussion on mentorship. Visit the Marquee Room to delve into what it means to be a mentor, finding the perfect match, and ensuring a supportive environment for junior scientists. See the full PEGS schedule here: https://bit.ly/4dGbYJ2
-
Great to be a part of YCharOS Inc.’s first annual symposium last week - an important meet-up of the YCharOS Industry Advisory Committee to discuss strategies to characterize antibodies against the entire human proteome. An ambitious yet vital project to improve reproducibility in scientific research and ultimately speed up progress towards better biological understanding and improved treatments and health outcomes for all 🙌 Find out more about the role of the Industry Advisory Committee, here: https://lnkd.in/eVrs6ZR6
Last week, we convened our inaugural face-to-face YCharOS meeting, bringing together representatives from Canadian funding agencies, antibody manufacturers, pharmaceutical companies, and academia at McGill University. The objective of the meeting was to strategize how to scale this academic initiative from testing antibodies for 100 proteins to the human proteome. Through panel discussions, reverse brainstorming (thanks Hannah C. – but is it typical to fill up the entire whiteboard in few minutes with potential future problems 😉), and various presentations, we identified several potential strategies that will require a few more weeks to digest. We'll provide a summary of the meeting along with our forward strategy. A big thank you to our antibody manufacturer partners—abcam, ABclonal Technology, Aviva Systems Biology,Bio-Techne, ABCD Antibodies, Cell Signaling Technology (CST), DSHB, GeneTex, Inc., Institute for Protein Innovation, Proteintech Group, Synaptic Systems GmbH, Thermo Fisher Scientific, YCharOS Inc. —for making the YCharOS project possible and for attending the meeting. Who can guess the type of IgG represented in that picture?
-
At Abcam, we rigorously validate our antibodies and proteins using advanced QC methods, ensuring the highest quality and reproducibility for your assays. Check out our poster #B003 at PEGS Boston this year to learn more about our quality processes. Learn more here: https://bit.ly/3Qqxh7H
-
We’re at PEGS Boston 2024! Find Abcam at the Danaher booth #500 & meet our experts: Deborah Moore-Lau, VP of Protein Development, and Will Howat, VP of Quality and Validation. Click the link for more info and to schedule a meeting with our team: https://bit.ly/3Qqxh7H
-
That first moment of inspiration feels great. But it’s even better when you show that it’s right. We’ve got over 32,000 high-performance antibodies to help you reach that moment. Together, we move forward faster. https://bit.ly/3bFUoaO